| Ident. | Authors (with country if any) | Title |
|---|
| 000020 |
Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] | Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients |
| 000101 |
Vanessa V. Dos Santos [Brésil] ; Ana Lúcia S. Rodrigues [Brésil] ; Thereza C. De Lima [Brésil] ; Susana R. De Barioglio [Argentine] ; Rita Raisman-Vozari [France] ; Rui D. Prediger [Brésil] | Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease |
| 000104 |
François Viallet [France] ; Séverine Pitel [France] ; Sylvie Lancrenon [France] ; Olivier Blin [France] | Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease |
| 000252 |
J. P. Azulay [France] | Évaluation d'un effet disease modifier dans la maladie de Parkinson : quel schéma d'étude? : MALADIE DE PARKINSON : PEUT-ON EN MODIFIER LE COURS EVOLUTIF ? |
| 000266 |
P. Cesaro [France] | Maladie de Parkinson : les enjeux du traitement : MALADIE DE PARKINSON : PEUT-ON EN MODIFIER LE COURS EVOLUTIF ? |
| 000280 |
A. Destee [France] | Comment évaluer l'effet neuroprotecteur en clinique ? : MALADIE DE PARKINSON : PEUT-ON EN MODIFIER LE COURS EVOLUTIF ? |
| 000300 |
Rui D. S. Prediger [Brésil] ; Aderbal S. Jr Aguiar [Brésil] ; Eduardo L. G. Moreira [Brésil] ; Filipe C. Matheus [Brésil] ; Adalberto A. Castro [Brésil] ; Roger Walz [Brésil] ; Andreza F. De Bem [Brésil] ; Alexandra Latini [Brésil] ; Carla I. Tasca [Brésil] ; Marcelo Farina [Brésil] ; Rita Raisman-Vozari [France] | The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinson's disease |
| 000353 |
Ngoc-Duc Doan [Canada] ; Steve Bourgault [Canada] ; Agnieszka Dejda [Canada] ; Myriam Letourneau [Canada] ; Michel Detheux [Belgique] ; David Vaudry [Canada, France] ; Hubert Vaudry [Canada, France] ; David Chatenet [Canada] ; Alain Fournier [Canada] | Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects |
| 000440 |
Fanny Schmiijt [France] ; Gael Le Douaron [France] ; Pierre Champy [France] ; Majid Amar [France] ; Blandine Seon-Meniel [France] ; Rita Raisman-Vozari [France] ; Bruno Figadere [France] | Tryptamine-derived alkaloids from Annonaceae exerting neurotrophin-like properties on primary dopaminergic neurons |
| 000529 |
| 22nd ECNP (European College of Neuropsychopharmacology) : d'après le e-journal en direct du congrès, Istanbul, Turquie, 12-16 septembre 2009 |
| 000592 |
S. Bourgault [Canada, France] ; D. Vaudry [France] ; A. Dejda [Canada, France] ; N. D. Doan [Canada, France] ; H. Vaudry [France] ; A. Fournier [Canada, France] | Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure-Activity Relationships of a Neuroprotective Peptide |
| 000627 |
Alan Haycox [Royaume-Uni] ; Christophe Armand [France] ; Susana Murteira [France] ; John Cochran [France] ; Clément Francois [France] | Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting |
| 000644 |
Joëlle Micallef [France] ; Marc Rey [France] ; Alexandre Eusebio [France] ; Christine Audebert [France] ; Frank Rouby [France] ; Elisabeth Jouve [France] ; Sophie Tardieu [France] ; Oliver Blin [France] | Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects |
| 000700 |
P. Remy [France] | Démontrer la neuroprotection dans la maladie de Parkinson : les études à "début retardé" |
| 000804 |
| Les nouvelles de la neuroprotection. I |
| 000818 |
P. Derkinderen [France] | Neuroprotection dans la maladie de Parkinson : est-ce encore bien raisonnable ? |
| 000942 |
R. Bordet [France] ; T. Ouk [France] ; S. Gautier [France] ; M. Laprais [France] ; D. Deplanque [France] ; P. Gele [France] ; M. Bastide [France] | Les récepteurs nucléaires PPAR : une nouvelle cible en neuropharmacologie ? |
| 000978 |
Stéphane Thobois [France] | Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease : A review of the literature |
| 000B24 |
Nathalie Turle-Lorenzo [France] ; Nathalie Breysse [France] ; Christelle Baunez [France] ; Marianne Amalric [France] | Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease |
| 000C92 |
A. Destee [France] | Neuroprotection et syndromes parkinsoniens neurodégénératifs |
| 000D82 |
S. Baker [France] ; E. Moyse [France] ; F. Jourdan [France] ; F. Colpaert [France] ; J. C. Martel [France] ; M. Marien [France] | Effects of the α2-ADRENORECEPTOR antagonist dexefaroxan on neurogenesis in the olfactory bulb of the adult rat in vivo: Selective protection against neuronal death |
| 000D99 |
Karine Parain [France] ; Céline Hapdey [France] ; Estelle Rousselet [France] ; Véronique Marchand [France] ; Bernard Dumery [France] ; Etienne C. Hirsch [France] | Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin |
| 000E14 |
| Parkinson et mouvements anormaux |
| 000E74 |
| Milestones in Research on Neurotoxins and Neuroprotection: A Tribute to Professor Toshiharu Nagatsu |
| 000E87 |
Jean Dessolin [France] ; Marie Schuler [France] ; Alice Quinart [France] ; Francesca De Giorgi [France] ; Leon Ghosez [France] ; Francois Ichas [France] | Selective targeting of synthetic antioxidants to mitochondria: towards a mitochondrial medicine for neurodegenerative diseases? |
| 000F12 |
Maria C. Obinu [France] ; Michel Reibaud [France] ; Véronique Blanchard [France] ; Saliha Moussaoui [France] ; Assunta Imperato [France] | Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence |
| 000F13 |
Wakako Maruyama [Japon] ; Yukihiro Akao [Japon] ; Maria Chrisina Carrillo [Argentine] ; Ken-Ichi Kitani [Japon] ; Moussa B. H. Youdium [Israël] ; Makoto Naoi [Japon] | Neuroprotection by propargylamines in Parkinson's disease: Suppression of apoptosis and induction of prosurvival genes |
| 000F41 |
Sophie Callier [France, Canada] ; Maryvonne Le Saux [France] ; Anne-Marie Lhiaubet [France] ; Thérèse Di Paolo [Canada] ; William Rostene [France] ; Didier Pelaprat [France] | Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture |
| 000F44 |
Aïcha Douhou [France] ; Thomas Debeir [France] ; Mario Gustavo Murer [Argentine] ; Louis Do [France] ; Noëlle Dufour [France] ; Véronique Blanchard [France] ; Saliha Moussaoui [France] ; Georg Andrees Bohme [France] ; Yves Agid [France] ; Rita Raisman-Vozari [France] | Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice |
| 001032 |
Oum-Kaltoum Hassani [France] ; Mireille Mouroux [France] ; Georg Andrees Bohme [France] ; Jean-Marie Stutzmann [France] ; Jean Feger [France] | Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain |
| 001043 |
Karine Parain [France] ; Véronique Marchand [France] ; Bernard Dumery [France] ; Etienne Hirsch [France] | Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice |
| 001114 |
P. Derkinderen [France] | Stratégies thérapeutiques conseillées à la phase initiale de la maladie |
| 001175 |
A. Boireau [France] ; P. Dubedat [France] ; F. Bordier [France] ; A. Imperato [France] ; S. Moussaoui [France] | The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation |
| 001179 |
Saliha Moussaoui [France] ; Maria-Carmen Obinu [France] ; Nadine Daniel [France] ; Michel Reibaud [France] ; Véronique Blanchard [France] ; Assunta Imperato [France] | The antioxidant Ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease |
| 001226 |
M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS |
| 001243 |
P. Jenner [Royaume-Uni] ; B.-Y. Zeng [Royaume-Uni] ; L. A. Smith [Royaume-Uni] ; R. K. B. Pearce [Royaume-Uni] ; B. Tel [Royaume-Uni] ; L. Chancharme [France] ; G. Moachon [France] | Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset |
| 001273 |
P. Remy [France] ; P. Hantraye [France] ; Y. Samson [France] | La tomographie par émission de positions, un outil de recherche fondamentale devenu indispensable à la recherche clinique : L'exemple des greffes neuronales dans la maladie de Parkinson |
| 001323 |
R. S. El-Bacha [France] ; P. Netter [France] ; A. Minn [France] | Mechanisms of apomorphine cytoxicity towards rat glioma C6 cells : protection by bovine serum albumin and formation of apomorphine-protein conjugates |
| 001351 |
F. A. Dajas-Bailador [Uruguay] ; M. Asencio [Chili] ; C. Bonilla [Uruguay] ; M. C. Scorza [Uruguay] ; C. Echeverry [Uruguay] ; M. Reyes-Parada [Uruguay] ; R. Silveira [Uruguay] ; P. Protais [France] ; G. Russell [Nouvelle-Zélande] ; B. K. Cassels [Chili] ; F. Dajas [Uruguay] | Dopaminergic pharmacology and antioxidant properties of pukateine, a natural product lead for the design of agents increasing dopamine neurotransmission |
| 001364 |
P. P. Michel [France] ; M. Marien [France] ; M. Ruberg [France] ; F. Colpaert [France] ; Yves Agid [France] | Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes |
| 001372 |
J. A. Aguirre [Espagne] ; A. Cintra [Suède] ; J. Hillion [Suède] ; J. A. Narvaez [Espagne] ; A. Jansson [Suède] ; T. Antonelli [Italie] ; L. Ferraro [Italie] ; F. A. Rambert [France] ; K. Fuxe [Suède] | A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse |
| 001402 |
A. Nieoullon [France] | Bases cellulaires des processus neurodégénératifs |
| 001407 |
C. Brefel-Courbon [France] ; C. Thalamas [France] ; H. Peyro Saint Paul [France] ; J.-M. Senard [France] ; J.-L. Montastruc [France] ; O. Rascol [France] | α2-Adrenoceptor antagonists: A new approach to Parkinson's disease? |
| 001423 |
E. Bezard [France] ; J.-M. Stutzmann [France] ; C. Imbert [France] ; T. Boraud [France] ; A. Boireau [France] ; C. E. Gross [France] | Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model |
| 001428 |
A. Boireau [France] ; M. Meunier [France] ; A. Imperato [France] | Ouabain-induced increase in dopamine release from mouse striatal slices is antagonized by riluzole |
| 001467 |
N. Aubin [France] ; O. Curet [France] ; A. Deffois [France] ; C. Carter [France] | Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice |
| 001553 |
P. P. Michel [France] ; M. Ruberg [France] ; Yves Agid [France] | Rescue of mesencephalic dopamine neurons by anticancer drug cytosine arabinoside |
| 001618 |
P. Morel [France] | Les perspectives thérapeutiques de la maladie de Parkinson |
| 001641 |
P. Barneoud [France] ; M. Mazadier [France] ; J.-M. Miquet [France] ; S. Parmentier [France] ; P. Dubedat [France] ; A. Doble [France] ; A. Boireau [France] | Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat |
| 001706 |
ABDELHAMID BENAZZOUZ [France] ; T. Boraud [France] ; P. Dubedat [France] ; A. Boireau [France] ; J.-M. Stutzmann [France] ; C. Gross [France] | Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey : a pilot study |
| 001753 |
| Effets neurotoxiques induits par des radicaux libres sur le système dopaminergique nigro-striatal. Etude d'agents protecteurs |
| 001787 |
A. Boireau [France] ; P. Dubedat ; F. Bordier ; C. Peny ; J.-M. Miquet ; G. Durand ; M. Meunier ; A. Doble | Riluzole and experimental parkinsonism : antagonism of MPTP-induced decrease in central dopamine levels in mice |
| 001805 |
A. Mouatt-Prigent [France] ; Yves Agid [France] ; E. C. Hirsch | Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease ? |
| 001947 |
P. P. Michel [France] ; Yves Agid [France] | The glutamate antagonist, MK-801, does not prevent dopaminergic cell death induced by the 1-methyl-4-phenylpyridinium ion (MPP+) in rat dissociated mesencephalic cultures |
